Peripheral Neuropathy
Damage or dysfunction of peripheral nerves, commonly causing burning pain, tingling, numbness, or weakness in the hands and feet. Cannabis has moderate evidence for reducing chronic neuropathic pain in adults, including peripheral neuropathy from diabetes, chemotherapy, or HIV.
- 16 states
- QUALIFYING IN
- Moderate
- EVIDENCE
- G62.9
- ICD-10
Reviewed by Laura H. Meyer
Qualifying states
What it is
Peripheral neuropathy is damage to or dysfunction of the peripheral nervous system (nerves outside the brain and spinal cord). Common causes include diabetes mellitus, chemotherapy, HIV infection, alcohol use, autoimmune disease, vitamin deficiency, infection, trauma, and inherited disorders. Symptoms typically include burning or shooting pain, tingling, numbness, weakness, and loss of coordination, most often in a stocking-glove distribution affecting feet first and then hands.
Cannabis and cannabis-derived therapies
The 2017 NASEM consensus report identified substantial evidence that cannabis is an effective treatment for chronic pain in adults. Peripheral neuropathy is a major chronic-pain subtype and was specifically included in several of the controlled trials that informed the NASEM finding.
Notable trial evidence includes:
- HIV-associated peripheral neuropathy: controlled trials of smoked cannabis (early 2000s) demonstrated pain reduction relative to placebo.
- Diabetic peripheral neuropathy: smaller controlled trials of inhaled and sublingual cannabinoids have shown pain reduction with dose-response patterns.
- Chemotherapy-induced peripheral neuropathy: observational and small-trial data are consistent with pain reduction; dedicated CIPN trials are sparse.
Both THC-dominant and CBD-dominant formulations have been studied, with mixed evidence on the relative contribution of each cannabinoid. Most positive trials have used preparations containing at least some THC.
Practical considerations
Cannabis is typically used adjunctively alongside standard neuropathic-pain therapy (gabapentin, pregabalin, duloxetine, tricyclics, topical agents). Patients should coordinate cannabis use with their neurologist, endocrinologist (for diabetic neuropathy), oncologist (for CIPN), or pain-management physician.
Drug interactions include additive CNS depression with gabapentinoids, opioids, and tricyclics. Cannabis may interact with warfarin and some antiretrovirals through CYP450 effects; patients on these medications should coordinate with their prescriber.
Important: peripheral neuropathy may signal underlying conditions (uncontrolled diabetes, B12 deficiency, autoimmune disease) that require disease-modifying treatment. Cannabis use should not substitute for evaluation and treatment of the underlying cause.
Frequently asked questions
How strong is the cannabis evidence for peripheral neuropathy?
Moderate. The 2017 NASEM consensus report found substantial evidence that cannabis is an effective treatment for chronic pain in adults, and neuropathic pain from peripheral neuropathy is a frequently studied subtype. Trials in HIV-associated neuropathy, diabetic neuropathy, and chemotherapy-induced peripheral neuropathy have shown reductions in pain intensity with both inhaled and oral cannabinoid preparations.
Is any cannabis-derived product FDA-approved for peripheral neuropathy?
No. No cannabis or cannabinoid product is FDA-approved specifically for peripheral neuropathy in the United States. Standard care uses gabapentin, pregabalin, duloxetine, tricyclic antidepressants, topical lidocaine or capsaicin, and for some patients tramadol or other opioids.
Which neuropathy subtypes have the most cannabis-related evidence?
HIV-associated peripheral neuropathy has the most controlled-trial data, dating to early-2000s studies showing pain reduction with smoked cannabis. Diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy have moderate evidence. Idiopathic small-fiber neuropathy and post-surgical neuropathic pain have less specific evidence but fall within the broader NASEM chronic-pain finding.
Which states qualify peripheral neuropathy for medical cannabis?
Several states explicitly enumerate peripheral neuropathy as a qualifying condition (Arkansas, Georgia, and others). Practitioner-discretion states (Oklahoma, New York post-2022, Missouri, Virginia post-2023) can certify for peripheral neuropathy. States that recognize severe chronic pain capture peripheral neuropathy within that broader category.
Sources
- NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 16, 2026
“Substantial evidence that cannabis is an effective treatment for chronic pain in adults.”
- NIH NINDS: Peripheral Neuropathyaccessed May 16, 2026